Table 2.

Cox proportional regression analyses with 6-month landmark stratified by agents. Tumorshrinkage categories are shown for each treatment cohort of patients.

	OS
	P-Value	HR (95% CI)
Overall Cohort
−100% to <−60%	<0.001	0.29 (0.22–0.39)
−60% to <−30%	0.005	0.77 (0.64–0.93)
−30% to <0%	Reference	Reference
0% to <+20%	0.002	1.39 (1.13–1.71)
≥+20%	0.011	1.52 (1.10–2.09)
No post-baseline imaging	0.5	1.16 (0.73–1.85)
Axitinib, sorafenib, or sunitinib
−100% to <−60%	<0.001	0.21 (0.15–0.31)
−60% to <−30%	0.009	0.67 (0.53–0.85)
−30% to <0%	Reference	Reference
0% to <+20%	0.002	1.66 (1.20–2.30)
≥+20%	0.2	1.44 (0.81–2.57)
No post-baseline imaging	0.4	0.69 (0.30–1.57)
Temsirolimus
−100% to <−60%	0.036	0.44 (0.20–0.95)
−60% to <−30%	0.5	0.86 (0.56–1.30)
−30% to <0%	Reference	Reference
0% to <+20%	0.1	1.46 (0.89–2.40)
≥+20%	0.046	2.38 (1.02–5.56)
No post-baseline imaging	0.6	1.42 (0.45–4.47)
IFN-α
−100% to <−60%	<0.001	0.33 (0.17–0.62)
−60% to <−30%	0.030	0.56 (0.34–0.95)
−30% to <0%	Reference	Reference
0% to <+20%	0.3	1.19 (0.84–1.67)
≥+20%	0.1	1.43 (0,90 -2.28)
No post-baseline imaging	0.4	1.38 (0.69 -2.76)